Search results for: Precision Medicine

OHE at ISPOR’s 20th Annual European Congress: Presentations

…medicines should also be reflected in the way opportunity cost is assessed so that benefits and benefits foregone are considered in commensurate terms. In concluding, Nancy noted that MCDA approaches…

Framing Effects and Study Design Considerations in Stated Preference Research

1 December 2017

…life: A stated preference discrete choice experiment. Social Science & Medicine, 124, pp.48-56. [available to download free-of-charge] For more information on OHE’s research on social values, please contact Koonal Shah….

Alan Maynard – Alas No More

5 February 2018

…second tells you what he thought – about regional inequalities in the NHS, putting the economics in evidence informed medicine where Cochrane and Sackett had stopped short, resisting the narrowing…

Environmental sustainability in the NHS 10 Year Health Plan: The need for green 

29 September 2025

…into electronic health records (EHRs) and clinical guidelines (e.g., flagging low-carbon treatment options using tools like the Medicine Carbon Footprint Formulary)  Develop and mandate carbon impact assessments for all clinical…

How to Analyse EQ-5D Data? Methods for Analysing and Reporting EQ-5D Data: The Indispensable New Guide

8 December 2020

…recently – in routine data collection in health care systems. (…) EQ-5D has become the cornerstone of health technology appraisal (HTA), affecting important decisions about access to new medicines. But despite…

‘HispaNICE’: the Creation of an ‘Independent Authority for the Evaluation of Health Practices and Policies’ Gathers Momentum

24 February 2021

…those currently developed by the Spanish Agency of Medicines and Medical Devices. The new institution would also foster the participation of relevant stakeholders into assessment stages, notably connecting existing centres…

Efficiency Measurement in Primary Care: Time to Overcome the Challenges and Achieve Some Gains

10 March 2021

…It is easy to be incorrectly comparing apples and oranges. For example, comparing activity levels or physical outputs – such the number of consultations provided, surgical procedures performed, or medicines…

Reconciling MCDA and Augmented Cost-Effectiveness Analysis: Do We Get the Same Decisions?

14 April 2021

…Garau, M., Schmitt, C., Kent, A. and Hutchings, A., (2013). A pilot study of multicriteria decision analysis for valuing orphan medicines. Value in Health, 16(8), pp.1163-1169. Devlin N., Sussex J.:…

Key Learnings From COVID-19: The Importance of Portfolio Management and How to Procure, Pay For, Distribute, and Use Vaccines During a Pandemic

21 April 2021

…(TPP), including vaccine efficacy and safety and immunogenicity, ease of delivery and storage, dose regimen, and durability of protection. The SC should ensure that the European Commission, the European Medicines…